Antares Pharma and Watson Pharmaceuticals have introduced Gelnique 3% (oxybutynin) gel 3%, for the treatment of overactive bladder (OAB).
The product is available in a metered pump dispenser and is delivered transdermally, resulting in a low level of side effects such as dry mouth and constipation, common with orally administered OAB medications.
Watson Global Brands executive vice president Fred Wilkinson said, "The clinical trial demonstrated an early treatment effect versus placebo and improved efficacy over time."
Gelnique 3%, approved by the FDA, was developed by Antares and was obtained through an exclusive licensing agreement by Watson.
Antares president and chief executive officer Paul Wotton said, "Watson's experience and commitment to urology coupled with their well-established and knowledgeable commercial team makes them the perfect partner to market this next generation gel product for the treatment of overactive bladder."